01. One receptor, two peptide lineages

Guanylate cyclase-C (GC-C, gene GUCY2C) is a transmembrane receptor on the luminal surface of the intestinal epithelium. It is the pharmacological target of a small peptide family: the endogenous hormones guanylin and uroguanylin, and the heat-stable enterotoxin (ST) of enterotoxigenic Escherichia coli. Agonism at GC-C raises cyclic guanosine monophosphate (cGMP) both inside and outside the enterocyte. Intracellular cGMP drives chloride and bicarbonate secretion into the gut lumen through the cystic fibrosis transmembrane conductance regulator (CFTR); extracellular cGMP acts on visceral afferent nerve terminals to dampen nociceptive signalling. The pairing of a secretory action with a visceral-analgesic one is the basis for the two GC-C agonist peptides that have become licensed medicines — linaclotide and plecanatide.

The two molecules descend from different arms of that family, and the difference shapes their pharmacology. One binds the receptor independently of pH across the whole gut; the other binds only where the lumen is acidic. That single structural difference, together with separate regulatory histories, is why the two peptides are not interchangeable on paper even though they share a receptor.

02. Linaclotide: a 14-amino-acid, pH-independent agonist

Linaclotide is a synthetic 14-amino-acid peptide structurally related to the guanylin peptide family. The European assessment report for its approved product describes it as a potent and selective GC-C agonist that acts locally at the luminal surface of the gastrointestinal tract with minimal systemic exposure; both linaclotide and its active metabolite bind the receptor. It lacks a sulfated tyrosine residue, and as a result its binding to GC-C is essentially pH-independent — it retains affinity across the pH range of the gut, from the proximal small intestine through to the colon.

Downstream, the intracellular cGMP rise increases chloride and bicarbonate secretion, and therefore intestinal fluid, with a reflex acceleration of transit. The extracellular cGMP fraction is understood to reduce pain-fibre activity, which is why the licensed product is described in European labelling as having both secretory and visceral-analgesic activity. These are laboratory and mechanistic findings, not therapeutic claims about an individual outcome.

03. Plecanatide: a 16-amino-acid uroguanylin analogue with pH-sensitive binding

Plecanatide is a synthetic 16-amino-acid analogue of human uroguanylin, carrying two disulfide bonds — the same disulfide architecture as the endogenous hormone. Its two acidic N-terminal residues (aspartate-2 and glutamate-3) make receptor binding pH-sensitive, so it activates GC-C maximally in the acidic environment of the duodenum and proximal jejunum and loses affinity as luminal pH rises more distally. In practice that gives it a more restricted zone of activation than linaclotide, a difference that has been characterised in computational and pharmacological modelling.

Plecanatide received its first regulatory approval from the US Food and Drug Administration in 2017. It has no UK or EU marketing authorisation. The FDA approval is cited here only to compare jurisdictions; it carries no weight as a UK regulatory fact.

04. What the randomised evidence shows

The clinical question both peptides were developed to answer is whether a GC-C agonist improves the two symptom domains of irritable bowel syndrome with constipation (IBS-C): bowel-movement frequency and abdominal pain. The endpoints used in the pivotal trials are symptom-based — for example complete spontaneous bowel movements per week and a responder definition for abdominal pain — rather than a biomarker or a disease-modification endpoint. Two independent syntheses support the class: a 2018 systematic review and network meta-analysis of secretagogues in IBS-C, and a later systematic review and meta-analysis of randomised controlled trials of linaclotide and plecanatide specifically. Both report benefit over placebo on those symptom endpoints.

The important limitation is the same one that applies across functional gut disorders: benefit is measured on patient-reported symptom scales, effect sizes are modest at the level of the individual, and trials are relatively short relative to a chronic condition. Evidence of this quality is enough for licensing because the endpoints were pre-specified and replicated, but it is not a claim that either peptide treats, cures or prevents any disease.

05. The UK licensing picture

Linaclotide is authorised in the UK as Constella, a prescription-only medicine (POM) for the symptomatic treatment of moderate-to-severe IBS-C in adults. It received a European marketing authorisation in November 2012, and the UK appraisal of its use in IBS-C sits within the NICE technology-appraisal and evidence-summary framework. One transatlantic divergence is worth flagging for anyone reading US material alongside UK material: the UK and EU label covers IBS-C in adults, not chronic idiopathic constipation (CIC), which is a separate condition covered under US labelling. A reader who assumes the two labels are identical will overstate the UK indication.

Plecanatide is the mirror image. It is a licensed medicine in the United States but has no MHRA marketing authorisation and no EU authorisation. In the UK it therefore sits outside the licensed-medicines framework: there is no UK-approved indication, no UK Summary of Product Characteristics, and no NICE appraisal. Any movement of the compound in the UK falls to be considered under the Medicines Act 1968 and the Human Medicines Regulations 2012, and — because it is not an authorised medicine here — it cannot be described as a UK treatment.

06. Evidence grade and framing

Where each peptide holds a marketing authorisation, the grade for its licensed indication is Strong: the evidence rests on multiple randomised controlled trials and independent meta-analyses, with pre-specified symptom endpoints and a plausible, well-characterised mechanism. That grade does not travel with the molecule across jurisdictions. Plecanatide is Strong for its US-licensed indications on US evidence, but in the UK it is an unlicensed research compound, and the practical UK grade is different from the US one.

This article is an evidence and regulatory explainer. It is framed for research and reference use only and gives no dosing, administration or self-use guidance. Decisions about any prescription medicine rest with a UK prescriber working from the current Summary of Product Characteristics and BNF; for plecanatide in the UK there is no authorised product and no such basis. Peptide Data does not claim that any peptide treats, cures or prevents any condition.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.